Hanmi Pharmaceutical Company Limited — Biomedical Watch V2

Traitements5programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
HGP2304-1A multicenter, randomized, double-blind, phase III study to evaluate efficacy and safety of HGP2304 in patients with essential hypertension	Hypertension	Phase 3	À vérifier	South Korea	À vérifier
HGP2304-2A multicenter, randomized, double-blind, phase III study to evaluate efficacy and safety of HGP2304 in patients with essential hypertension	Hypertension	Phase 3	À vérifier	South Korea	À vérifier
RLD2209-1A multicenter, randomized, double-blind, phase III study to evaluate efficacy and safety of HGP2304 in patients with essential hypertension	Hypertension	Phase 3	À vérifier	South Korea	À vérifier
RLD2209-2A multicenter, randomized, double-blind, phase III study to evaluate efficacy and safety of HGP2304 in patients with essential hypertension	Hypertension	Phase 3	À vérifier	South Korea	À vérifier
HGP2304-1A multicenter, randomized, double-blind, phase III study to evaluate efficacy and safety of HGP2304 in patients with essential hypertension	Hypertension	Phase 3	À vérifier	South Korea	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
HGP2304-1	Hypertension	Phase 3	NCT06174766	A Study to Evaluate Efficacy and Safety of HGP2304 in Essential Hypertension Patients	COMPLETED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.